Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc.

Overview
Date Founded

1996

Headquarters

One amgen Center Drive,Thousand Oaks, CA 91320

Type of Company

Private

Employees (Worldwide)

501 - 1,000

Industries

Pharmaceuticals
Retail: Drug Stores
Medical Support Services
Biotechnology

Company Description

Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. At Onyx, we are grounded in three leadership hallmarks that guide how we manage our business and build value for patients and shareholders: innovation, patient-centeredness and stewardship.

Contact Data
Trying to get in touch with decision makers at Onyx Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Financial Officer & Vice President

General Counsel

Senior Vice President & Chief Commercial Officer

Vice President & Head-Global Medical & Scientific Affairs

Head of Human Resources

Senior Director, Strategic Operations

Executive Vice President, Corporate Development & Strategy

Senior Vice President-Commercial Operations

Executive Director of Oncology Marketing

Executive Director

Board of Directors

Former Chief Executive Officer at ARYx Therapeutics Inc.

Paths to Onyx Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Onyx Pharmaceuticals, Inc.
Recent Transactions
Details Hidden

Amgen, Inc. purchases Onyx Pharmaceuticals, Inc.

Details Hidden

Onyx Pharmaceuticals, Inc. issued Common Stock

Details Hidden

Onyx Pharmaceuticals, Inc. purchases Proteolix, Inc.

Transaction Advisors
Underwriter

Advised onOnyx Pharmaceuticals, Inc. issued Common Stock

Underwriter

Advised onOnyx Pharmaceuticals, Inc. issued Common Stock

Underwriter

Advised onOnyx Pharmaceuticals, Inc. issued Common Stock

Investment Advisor

Advised onAmgen, Inc. purchases Onyx Pharmaceuticals, Inc.

Legal Advisor

Advised onAmgen, Inc. purchases Onyx Pharmaceuticals, Inc.

Legal Advisor

Advised onAmgen, Inc. purchases Onyx Pharmaceuticals, Inc.

Advisors & Consultants
Legal Advisor

Partner, Palo Alto at Cooley LLP

Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Legal Advisor

Partner, Palo Alto at Cooley LLP

Clients

The Cal Alumni Association (CAA) provides all Cal graduates with rewarding connections to the University, to fellow alumni, and to current students. Founded by the original graduates of the University of California in 1872, the Cal Alumni Association today represents nearly half a million alumni living throughout the world. With a mission of advancing and promoting the interests of the University, CAA is committed to providing essential programs and services designed to keep alumni of all ages and interests connected to the University and to each other.

Key Stats and Financials As of
Market Capitalization
$9.06B
Total Enterprise Value
Earnings Per Share
Non-Profit Donations & Grants
Investments
Details Hidden

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Investors
Details Hidden

Sequoia Capital invests in seed to early stage companies. The firm focuses on energy, financial services, healthcare, Internet, mobile and technology sectors. Within the energy sector, the firm seeks to partner with start-ups focused on the alternative energy, conventional energy, energy efficiency, energy storage and energy services markets.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Onyx Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Onyx Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Onyx Pharmaceuticals, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/onyx-pharmaceuticals-inc-22325
  • https://relationshipscience.com/organization/onyx-pharmaceuticals-inc-22325